Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

FDA approves injectable drug to treat opioid-dependent patients
Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE.
Ongoing Oxidative Stress Causes Subclinical Neuronal Dysfunction in the Recovery Phase of EAE.
Multiple Sclerosis: Myeloperoxidase Immunoradiology Improves Detection of Acute and Chronic Disease in Experimental Model.
Immune surveillance in multiple sclerosis patients treated with natalizumab.
About Tysabri
Prevalence of stress urinary incontinence in women with multiple sclerosis.
[Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids].
Medication withdrawal in relapsing-remitting multiple sclerosis: why not?
Relapses in patients treated with fingolimod after previous exposure to natalizumab.
Assessment and classification of early stage multiple sclerosis with inertial sensors: comparison against clinical measures of disease state.
Autoreactive CD19+CD20- Plasma Cells Contribute to Disease Severity of Experimental Autoimmune Encephalomyelitis.
Novel 3D analysis of Claudin-5 reveals significant endothelial heterogeneity among CNS microvessels.
Astrocytes regulate myelin clearance through recruitment of microglia during cuprizone-induced demyelination.
Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Overcoming Unresponsiveness in Experimental Autoimmune Encephalomyelitis (EAE) Resistant Mouse Strains by Adoptive Transfer and Antigenic Challenge.
Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice.
Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
Endocannabinoids and neurodegenerative diseases.
Comprehensive Immunophenotyping of Cerebrospinal Fluid Cells in Patients with Neuroimmunological Diseases.
Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?
"Putting One Foot in Front of the Other": A Qualitative Study of Emotional Experiences and Help-Seeking in Women with Multiple Sclerosis.
Efficacy and safety of Alemtuzumab in treatment-naive patients with relapsing-remitting multiple sclerosis: Four-year follow-up of the Care-MS I study.
The next generation of exoskeletons: lighter, cheaper devices are in the works.
FTY720 (Fingolimod) Attenuates Beta-amyloid Peptide (Aβ(42))-Induced Impairment of Spatial Learning and Memory in Rats.

Pages